Cargando…
Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo
OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the ef...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650836/ https://www.ncbi.nlm.nih.gov/pubmed/33177820 http://dx.doi.org/10.2147/IJN.S266165 |
_version_ | 1783607565790216192 |
---|---|
author | Liu, Zhenguang Yu, Lin Gu, Pengfei Bo, Ruonan Xu, Shuwen Wusiman, Adelijiang Liu, Jiaguo Hu, Yuanliang Wang, Deyun |
author_facet | Liu, Zhenguang Yu, Lin Gu, Pengfei Bo, Ruonan Xu, Shuwen Wusiman, Adelijiang Liu, Jiaguo Hu, Yuanliang Wang, Deyun |
author_sort | Liu, Zhenguang |
collection | PubMed |
description | OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the effects of surface chemistry on the adjuvant activity of Ganoderma lucidum polysaccharide cubosomes (GLPC) by placing two kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB) and poly(diallydimethyl ammonium chloride) (PDDAC), on their surface. RESULTS: CTAB- or PDDAC-modified GLPC were found to significantly promote humoral and cellular immune responses, as well as the proliferation of CD3+ CD4+ or CD3+ CD8+T cells through the powerful activation of dendritic cells (DCs). The enhanced immune responses of PDDAC-modified GLPC might be attributed to the maturation of DCs into draining lymph nodes and the activation of spleen and cytokines in serum. CONCLUSION: PDDAC modification is beneficial for enhancing humoral and cellular immune response, suggesting that PDDAC-GLPC-OVA has the ability to be a potential adjuvant for vaccine. |
format | Online Article Text |
id | pubmed-7650836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76508362020-11-10 Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo Liu, Zhenguang Yu, Lin Gu, Pengfei Bo, Ruonan Xu, Shuwen Wusiman, Adelijiang Liu, Jiaguo Hu, Yuanliang Wang, Deyun Int J Nanomedicine Original Research OBJECTIVE: Recent studies have revealed the adjuvant activity of cubosomes and their potential utility as an antigen delivery system. In this study, to further enhance the adjuvant activity of cubosomes, two cationic polymers are modified on the surface of cubosomes. METHODS: Here, we exploit the effects of surface chemistry on the adjuvant activity of Ganoderma lucidum polysaccharide cubosomes (GLPC) by placing two kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB) and poly(diallydimethyl ammonium chloride) (PDDAC), on their surface. RESULTS: CTAB- or PDDAC-modified GLPC were found to significantly promote humoral and cellular immune responses, as well as the proliferation of CD3+ CD4+ or CD3+ CD8+T cells through the powerful activation of dendritic cells (DCs). The enhanced immune responses of PDDAC-modified GLPC might be attributed to the maturation of DCs into draining lymph nodes and the activation of spleen and cytokines in serum. CONCLUSION: PDDAC modification is beneficial for enhancing humoral and cellular immune response, suggesting that PDDAC-GLPC-OVA has the ability to be a potential adjuvant for vaccine. Dove 2020-11-04 /pmc/articles/PMC7650836/ /pubmed/33177820 http://dx.doi.org/10.2147/IJN.S266165 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Zhenguang Yu, Lin Gu, Pengfei Bo, Ruonan Xu, Shuwen Wusiman, Adelijiang Liu, Jiaguo Hu, Yuanliang Wang, Deyun Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title | Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title_full | Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title_fullStr | Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title_full_unstemmed | Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title_short | Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo |
title_sort | surface-engineered cubosomes serve as a novel vaccine adjuvant to modulate innate immunity and improve adaptive immunity in vivo |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650836/ https://www.ncbi.nlm.nih.gov/pubmed/33177820 http://dx.doi.org/10.2147/IJN.S266165 |
work_keys_str_mv | AT liuzhenguang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT yulin surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT gupengfei surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT boruonan surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT xushuwen surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT wusimanadelijiang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT liujiaguo surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT huyuanliang surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo AT wangdeyun surfaceengineeredcubosomesserveasanovelvaccineadjuvanttomodulateinnateimmunityandimproveadaptiveimmunityinvivo |